Skip to main content
PHAR logo

Pharming Group N.V. (PHAR) Stock: Price, Forecast & Analyst Target

Pharming Group N.V. (PHAR) — MoonshotScore 69/100 (Strong band), calculated Nov 18, 2026. Price $11.54 (-5.10%), as of the Nov 20, 2026 trading session; market cap $817M.

Educational signal · not a buy or sell recommendation · How to read this

$11.54 −$0.62 (-5.10%) Market Cap $817M

Pharming Group N.V. · PHAR · NASDAQ

Pharming Group N.V. is a biopharmaceutical company focused on developing and commercializing protein replacement therapies and precision medicines for the treatment of rare diseases. The company's lead product, Ruconest, addresses acute hereditary angioedema.

Price as of Nov 20, 2026

Key Statistics

69 of 100

MoonshotScore v2 · Pharming Group (PHAR)

Strong
Business Quality Elite (88)
Financial Safety Sound (61)
Valuation Fair (62)
Growth Durability Fading (20)
Momentum Rising (62)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Elite quality, but stalling growth. Business Quality: Elite; Financial Safety: Sound; Valuation: Fair; Growth Durability: Fading; Momentum: Rising.

  • EPS beat 1 of the last 4 reports
  • Altman Z 3.15 · Piotroski F 5
  • ROE 8.7% · ROA 6.4% · current ratio 3.23

Holding back: soft growth

Helping: business quality

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for PHAR (53 recorded, newest six shown)
RecordedScoreBand
84Exceptional
84Exceptional
84Exceptional
69Strong
69Strong
69Strong

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$11.54
Change on the day-5.10%
52-week range$9.11 – $21.34
Market capitalisation$817M—
Price / earnings (trailing)35.00
Shares traded on the day10.5K

Price & events

Other perspectives

Council score for Pharming Group (PHAR): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Strong
Financial Safety Moderate
Valuation Moderate
Growth Durability Weak
Momentum Moderate

Legends Council

3 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Englander-style lens (simulated) Izzy Englander Unfavorable read
Klarman-style lens (simulated) Seth Klarman Neutral read
Moon AI lens (model) Neutral read

Read on: Nov 20, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Neutral
Margin of Safety Fairly Valued
Profit Margin Neutral
Debt/Equity Neutral
ROE Neutral
Gross Margin Strong

Read on: Nov 19, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Nov 19, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 21, 2026, except a card that shows its own read date.

1 · What is it?

What is Pharming Group (PHAR), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Pharming Group N.V. (PHAR) is listed on NASDAQ. It employs 407 people and is led by Kenneth Lynard. The market values it at $817M.

2 · Latest results

What do the latest results show for Pharming Group (PHAR)?

Short answer · as of

Against analyst estimates the company has EPS beat 1 of the last 4 reports.

Quarterly income statement — 3 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Sep 2025$97M$8M—
Q4 FY2025$107M$5M$0.07 (diluted)
Q1 FY2026$72M-$5M-$0.07 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Pharming Group (PHAR)?

Short answer

The MoonshotScore pillars rate business quality as strengths. What is holding it back is soft growth. The distress and quality screens read Altman Z 3.15 · Piotroski F 5. Trailing ratios: ROE 8.7% · ROA 6.4% · current ratio 3.23.

4 · What to check next?

What should you watch next at Pharming Group (PHAR)?

Short answer · as of

Current published price targets run low $38.00 · high $38.00 · consensus $38.00 · median $38.00 against a quoted price of $11.54 (as of Nov 20, 2026).

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.
  • The next earnings date is not yet scheduled in the calendar we read.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Pharming Group compare with its peers?

Short answer

Pharming Group's score ranks tied for 8th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Eton Pharmaceuticals, Inc. (ETON) Same industry, near in market value$60.85 Nov 20, 2026$1.76B98 5-pillar Nov 18, 2026
Nurix Therapeutics, Inc. (NRIX) Same industry, near in market value$12.85 Nov 20, 2026$1.40B97 5-pillar Nov 18, 2026
Innoviva, Inc. (INVA) Same industry, near in market value$18.41 Nov 20, 2026$1.31B96 5-pillar Nov 18, 2026
Zevra Therapeutics, Inc. (ZVRA) Same industry, near in market value$8.76 Nov 20, 2026$521M91 5-pillar Nov 18, 2026
Fennec Pharmaceuticals Inc. (FENC) Same industry, near in market value$13.45 Nov 19, 2026$475M91 5-pillar Nov 18, 2026
Rigel Pharmaceuticals, Inc. (RIGL) Same industry, near in market value$40.09 Nov 20, 2026$755M88 5-pillar Nov 18, 2026
AnaptysBio, Inc. (ANAB) Same industry, near in market value$46.63 Nov 20, 2026$1.39B76 5-pillar Nov 18, 2026
Pharming Group (PHAR) — this page$11.54$817M69
LB Pharmaceuticals Inc (LBRX) Same industry, near in market value$38.85 Nov 20, 2026$1.26B69 5-pillar Nov 18, 2026
Climb Bio, Inc. (CLYM) Same industry, near in market value$9.19 Nov 20, 2026$540M68 5-pillar Nov 18, 2026
Vor Biopharma, Inc. (VOR) Same industry, near in market value$19.19 Nov 20, 2026$1.18B66 5-pillar Nov 18, 2026
SpyGlass Pharma, Inc. Common Stock (SGP) Same industry, near in market value$30.43 Nov 20, 2026$1.02B64 5-pillar Nov 18, 2026
MeiraGTx Holdings plc (MGTX) Same industry, near in market value$7.98 Nov 20, 2026$780M63 5-pillar Nov 18, 2026

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$38.00 – $38.00
Consensus target
$38.00
Median target
$38.00

Consensus record · Captured .

Measured against a quoted price of $11.54 (as of Nov 20, 2026).

Insider activity

Form 4 records via FMP · Most recent available transactions

Transactions
1
Identified insiders
1
Purchases
0
Sales
0
Other transactions
1

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held PHAR in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported PHAR in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What Investors Ask About Pharming Group (PHAR)

These answers are editorial: 1 of these 9 answers is drawn from the PHAR research dossier (written May 10, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for PHAR?

PHAR carries the MoonshotScore stated above — the Strong band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.

Is PHAR a good stock to buy?

Stock Expert AI does not rate PHAR buy, sell or hold. Pharming Group N.V. carries a MoonshotScore, in the Strong band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the PHAR stock price today?

The last price recorded for Pharming Group N.V. (PHAR), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the PHAR price target?

The analyst consensus price target for Pharming Group N.V. (PHAR), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

What are the main risks for PHAR?

The main risks for Pharming Group N.V. include competition from other therapies for hereditary angioedema (HAE), regulatory hurdles and potential delays in drug approval processes, patent expiration and generic competition, and economic downturns and healthcare cost containment measures. Additionally, currency fluctuations can affect the value of the ADR.

What are the key factors to evaluate for PHAR?

Pharming Group N.V. (PHAR) holds a MoonshotScore in the moderate range. To weigh it, compare the trailing P/E under Price & valuation with the analyst view under Analyst targets & estimates on this page. The company's lead product, Ruconest, addresses a critical need in the treatment of acute hereditary angioedema (HAE). Not financial advice.

How frequently does PHAR data refresh on this page?

PHAR's price is the last quote we recorded, from the Nov 20, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven PHAR's recent stock price performance?

Pharming Group N.V. (PHAR) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Lead product Ruconest addresses a critical need in HAE treatment. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider PHAR overvalued or undervalued right now?

The trailing P/E of Pharming Group N.V. (PHAR) is listed under Price & valuation, and the analyst consensus target under Analyst targets & estimates, on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 18 figures on this page — 11 from Financial Modeling Prep (FMP), 6 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.